<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">Cerebral vasospasm</z:e> following <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) is a significant cause of morbidity and mortality and recent studies indicate that Rho-kinase plays an important role in the occurrence of such <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Eicosapentaenoic acid (<z:chebi fb="113" ids="28364">EPA</z:chebi>), an n-3 polyunsaturated fatty acid, inhibits sphingosylphosphorylcholine (SPC)-induced Rho-kinase activation in vitro, so this study examined whether <z:chebi fb="113" ids="28364">EPA</z:chebi> prevented <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> occurrence after SAH in patients </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The trial population was 101 patients with SAH subjected to craniotomy and clip application </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="113" ids="28364">EPA</z:chebi> was orally administered at a daily dose of 1800 mg <z:chebi fb="113" ids="28364">EPA</z:chebi> from day 4 to day 14 to 73 patients; the other 28 constituted the control group, receiving no <z:chebi fb="113" ids="28364">EPA</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="113" ids="28364">EPA</z:chebi> significantly curtailed both the occurrence of symptomatic vasospasm (14% <z:chebi fb="113" ids="28364">EPA</z:chebi> group, 36% control, P = 0.019) and of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> because of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> (4% <z:chebi fb="113" ids="28364">EPA</z:chebi> group, 29% control, P = 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, the percentage of patients with a clinically good outcome was significantly higher in the <z:chebi fb="113" ids="28364">EPA</z:chebi> group (85%, P = 0.022) than in control (64%); there were no <z:hpo ids='HP_0011420'>deaths</z:hpo> in the <z:chebi fb="113" ids="28364">EPA</z:chebi> group but three (11%) in control (P = 0.020) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: These findings suggest <z:chebi fb="113" ids="28364">EPA</z:chebi> inhibits symptomatic <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> after SAH and also improves clinical prognosis </plain></SENT>
</text></document>